Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Operating expenses: | ||||||
| Research and development expenses | $ 2,343,154 | $ 1,081,705 | $ 6,539,948 | $ 1,988,450 | $ 3,496,796 | $ 1,412,409 |
| General and administrative expenses | 1,653,072 | 1,151,542 | 4,341,880 | 2,798,766 | 4,289,831 | 5,563,192 |
| Total operating costs and expenses | 5,095,586 | 2,233,247 | 11,981,188 | 4,787,216 | 7,786,627 | 6,975,601 |
| Ratchet share expense | 1,099,360 | 1,099,360 | ||||
| Loss from operations | (5,095,586) | (2,233,247) | (11,981,188) | (4,787,216) | (7,786,627) | (6,975,601) |
| Other income (expense): | ||||||
| Interest expense | (1,716) | (451,306) | (1,820) | (827,539) | (827,539) | (32,226) |
| Interest income | 348 | 708 | 1,249 | 1,501 | 2,012 | 679 |
| Paycheck protection program loan forgiveness | 62,500 | 62,500 | ||||
| Australian research and development incentives | 65,111 | 230,188 | 43,666 | |||
| Change in fair value of embedded features | (96,000) | (203,000) | (203,000) | 5,000 | ||
| Change in fair value of warrant liability | 128,030 | (100,780) | 128,030 | (1,546,280) | (1,546,280) | (19,600) |
| Loss on extinguishment of convertible notes and convertible notes, related parties | (2,322,943) | (2,322,943) | (2,322,943) | |||
| Other income (expense), net | 191,773 | (2,970,321) | 357,647 | (4,898,261) | (4,791,584) | 16,353 |
| Net loss | (4,903,813) | (5,203,568) | (11,623,541) | (9,685,477) | (12,578,211) | (6,959,248) |
| Net loss attributable to noncontrolling interests | (7,130) | (74,331) | (74,331) | (322,588) | ||
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (4,903,813) | $ (5,196,438) | (12,074,119) | $ (9,611,146) | $ (12,503,880) | $ (6,636,660) |
| Deemed dividend on warrant modification | $ (450,578) | |||||
| Net loss per share | ||||||
| Net loss per share basic | $ (0.48) | $ (1.02) | $ (1.39) | $ (2.06) | $ (2.37) | $ (1.50) |
| Net loss per share diluted | $ (0.48) | $ (1.02) | $ (1.39) | $ (2.06) | $ (2.37) | $ (1.50) |
| Weighted average common shares outstanding basic | 10,165,622 | 5,119,121 | 8,713,570 | 4,668,635 | 5,278,435 | 4,427,242 |
| Weighted average common shares outstanding diluted | 10,165,622 | 5,119,121 | 8,713,570 | 4,668,635 | 5,278,435 | 4,427,242 |
| X | ||||||||||
- Definition Australian research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Change in fair value of embedded features. No definition available.
|
| X | ||||||||||
- Definition Deemed dividend on warrant modification. No definition available.
|
| X | ||||||||||
- Definition Represents the gain on Paycheck Protection Program loan forgiveness. No definition available.
|
| X | ||||||||||
- Definition Ratchet share expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|